SANTA MONICA, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA), one of mainland China's leading pharmaceutical companies, today announced that it was granted an additional patent related to its Rh-Apo2L anti-cancer drug, the second of three patents that had been applied for which Aida believes places it at the vanguard of China's pharmaceutical industry. The patent was jointly granted by China's State Intellectual Property Office ("SIPO") to East China University of Science& Technology ("ECUST") and Aida's majority-controlled subsidiary, Shanghai Quiaer Biotechnology Company, Ltd ("Shanghai Qiaer"). ECUST is the partner with Aida in the research of this field.
The patent, certificate number: 200510028037.6, deals with the cultivation of Rh-Apo2L. The main content of the patent includes the following:
-- the fermentative process dividing into five stages,
-- the different stage separately increasing the different C/N culture
-- realization of C and N demand balance, and
-- that the methodology set by Aida can effectively enhance the soluble
protein expression quantity while simultaneously reducing the
fermentative process of the ethanoic acid accumulation.
Mr. Jinsong Zhou, the CEO of Shanghai Qiaer stated, "This continues to establish Aida as a technology leader in not only the Chinese pharmaceutical field, but also in the international arena. Our scientists and researchers are deeply encouraged by the news and will reinforce our confidence in the ongoing clinical trials of Rh-Apo2L."
About Rh-Apo2L -- The Anti-Cancer Drug
Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat
certain forms of cancer. Rh-Apo2L has completed the Phase I clinical trials
successfully in July 2006. This biopharmaceutical drug has gained the
attention of researchers and clinical professionals throughout China who
are observing the drug f
|SOURCE Aida Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved